Vericel Delivers Record Revenue and Profitability in Q3 2025—MACI Growth and Strong Cash Position Highlight Positive Outlook
Record Third Quarter Revenue and Surge in MACI Sales Lead the Way
Vericel’s third quarter of 2025 stands out for its exceptional performance across key financial metrics. The company reported total revenue of $67.5 million for the quarter, marking a new high-water mark, fueled by MACI sales that surged 25% year-over-year to $55.7 million. Burn Care products added $11.8 million in revenue, including a standout performance from NexoBrid, which achieved record quarterly growth.
This growth wasn’t just at the top line. Net income swung to $5.1 million—up from a loss last year—and non-GAAP adjusted EBITDA rose a striking 69% to $17 million. With an operating cash flow of $22.1 million for the quarter and a gross margin of 73.5%, Vericel demonstrates increasing operational leverage as its flagship MACI franchise scales. The table below highlights the quarter’s most important financial figures:
| Q3 2025 | Q3 2024 | % Change | |
|---|---|---|---|
| Total Revenue ($M) | 67.50 | 57.91 | 16.5% |
| MACI Revenue ($M) | 55.70 | 44.70 | 24.7% |
| Burn Care Revenue ($M) | 11.80 | 13.30 | -11.3% |
| Gross Margin | 73.5% | 71.9% | +1.6 pts |
| Net Income ($M) | 5.10 | (0.90) | n/m |
| Adjusted EBITDA ($M) | 17.00 | 10.04 | 69.4% |
| Operating Cash Flow ($M) | 22.10 | n/a | n/a |
Financial Strength: Strong Cash Reserves, No Debt, and Healthy Margins
Vericel exited the quarter with $185 million in cash and investments and no debt, putting the company in an enviable financial position as it invests in expanding its MACI sales force and clinical programs. Operating expenses increased moderately, primarily due to increased headcount and the ramp-up of a new facility, but margin expansion more than offset these costs. The gross margin rose to 73.5%, up from 71.9% a year earlier, reflecting the strong demand and operational scale of MACI.
Key indicators highlight a business firing on all cylinders: not only has Vericel maintained high margins and growth, but it’s also showing healthy operating leverage as adjusted EBITDA now comprises 25% of total revenue. Net income per diluted share jumped to $0.10 compared to a loss of $0.02 in the year-ago period.
Operational Highlights: MACI Franchise Accelerates, New Surgeons Onboarded
The growth in MACI was supported by record numbers of biopsies and more than 800 MACI Arthro surgeons trained to date—a milestone reflecting expanding market reach. Vericel also delivered its best-ever quarter for NexoBrid revenue, with 38% growth year-over-year. The sales force expansion remains on track for full deployment at the start of 2026, and the clinical study for the MACI Ankle program is set to launch in Q4 2025.
Outlook: Positive Momentum Heading Into Year-End and 2026
Management reaffirmed full-year revenue guidance between $272 million and $276 million and sees MACI growth continuing in the low 20% range. The gross margin target remains at a robust 74%, with adjusted EBITDA expected to reach 26% of revenue. With growing product demand, disciplined expense management, and a healthy pipeline, Vericel appears poised to deliver on its promise of sustained, profitable growth.
Takeaway: Robust Execution and Market Expansion Point to Strong Finish and Further Upside
For investors and industry watchers, Vericel’s latest quarter demonstrates more than just solid numbers—it reveals a business with strong demand drivers, increasing efficiency, and ample resources to support long-term growth initiatives. With record performance now in the books, Vericel enters the year-end with momentum and the financial strength to keep scaling its platform. This is a company that continues to set a high bar for execution in the biotech specialty space.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI